Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However,
ongoing surveillance has revealed the emergence of variants harboring mutations in …

The SARS-CoV-2 Omicron variant (B.1.1.529) contains mutations that mediate escape from
antibody responses, although the extent to which these substitutions in spike and non-spike …

Background Understanding immunogenicity and effectiveness of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical to guide rational use. Methods We …

Although children have been largely spared from coronavirus disease 2019 (COVID-19), the
emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of …

PURPOSE The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients
with cancer are poorly understood. METHODS We performed a prospective cohort study of …

Background Nursing home (NH) residents have borne a disproportionate share of SARS-CoV-2
morbidity and mortality. Vaccines have limited hospitalisation and death from earlier …

Initial exposure to a pathogen elicits an adaptive immune response to control and eradicate
the threat. Interrogating the abundance and specificity of the naive B cell repertoire drives …

After BNT162b2 messenger RNA vaccination, antibody levels to spike, receptor-binding
domain, and virus neutralization were examined in 149 nursing home residents and 110 …

The SARS-CoV-2 pandemic impact on nursing home (NH) residents prompted their prioritization
for early vaccination. To fill the data gap for vaccine immunogenicity in NH residents, …

Antibody decline occurred from 2 weeks to 6 months post-BNT162b2 mRNA vaccination in
nursing home (NH) residents and healthcare workers. Antispike, receptor-binding domain, …